STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Stemline Therapeutics, Inc.

750 Lexington Avenue
Eleventh Floor
New York, NY 10022
United States
646-502-2311
http://www.stemline.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedAge
Dr. Ivan Bergstein M.D.Founder, Chairman and Chief Exec. Officer937.32kN/A51
Mr. David G. GioncoChief Accounting Officer and VP of Fin.441.88kN/A57
Mr. Kenneth HobermanChief Operating Officer and Corp. Sec.642.74kN/A52
Dr. Eric K. Rowinsky M.D.ConsultantN/AN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Corporate Governance

Stemline Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.